- Question
- Can vutrisiran, an RNA interference agent that lowers hepatic transthyretin production, improve outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)?
- Design
- Phase 3, randomized 1:1, double-blind, placebo-controlled, multicenter trial of 655 patients with up to 36 months of treatment. Efficacy endpoints were assessed in the overall population and in the monotherapy population (not on tafamidis at baseline) and tested hierarchically.
- Population
- Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including both those receiving tafamidis at baseline and those who were not.
- Intervention
- Vutrisiran 25 mg administered subcutaneously every 12 weeks for up to 36 months (326 patients).
- Control
- Matching subcutaneous placebo every 12 weeks (329 patients).
- Primary outcome
- Composite of death from any cause and recurrent cardiovascular events (cardiovascular hospitalizations and urgent heart failure visits).
- Results
- Vutrisiran lowered the primary composite endpoint versus placebo (HR in the overall population 0.72; 95% CI 0.56 to 0.93; P = 0.01; HR in the monotherapy population 0.67; 95% CI 0.49 to 0.93; P = 0.02). All-cause mortality through 42 months was also lower (HR 0.65; 95% CI 0.46 to 0.90; P = 0.01).
- Safety
- Adverse events were similarly frequent in both groups (99% with vutrisiran and 98% with placebo); serious adverse events occurred in 62% and 67% of patients, respectively.
- Conclusion
- In patients with ATTR-CM, vutrisiran reduced the risk of death from any cause and of cardiovascular events compared with placebo, and preserved functional capacity and quality of life.
- Why it matters
- It provided evidence that silencing hepatic transthyretin production improves clinical outcomes in ATTR-CM, broadening the therapeutic options for a progressive and fatal disease.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 7, 2026